PDIA5

Across TCGA pan-cancer cohorts, PDIA5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDIA5 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PDIA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDIA5 expression acts as an unfavorable survival marker.

KIRP, UCEC, and STAD are the cancer types where PDIA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.594	0.903	.015	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	II,III,IV	0.174	0.567	.039	3	view →
COAD	OS	Median	All	0.216	0.678	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDIA5–KIRP (OS)

Open the KIRP breakdown →